Systematic Literature Review of Factor Xa Inhibitors in Real-World Clinical Settings
A major pharmaceutical manufacturer of a Factor Xa inhibitor partnered with
Polygon Health Analytics to assess real-world safety and effectiveness of
widely prescribed anticoagulants across the European Union.
Client Challenge
The client needed to understand how various Factor Xa inhibitors
performed outside of clinical trials - in everyday patient care scenarios.
This required a comprehensive review of independent, non-sponsored studies that
covered real-world outcomes such as stroke, bleeding, and mortality.
Our Research Approach
Over a 6-month engagement, our team conducted a systematic literature review spanning peer-reviewed publications from 2022 to 2024. Our scope focused on:
Outcomes such as stroke, systemic embolism, major bleeding, and all-cause mortality
Exclusion of industry-sponsored studies to ensure unbiased results
Quality appraisal and standardized data abstraction methods
Key Outcomes & Industry Impact
Found consistent safety and efficacy profiles across major Factor Xa inhibitors.
Identified real-world patient trends not reflected in controlled clinical trials.
Results accepted for presentation at ISPOR 2025, the leading HEOR conference.
Equipped client with evidence-based insights for strategic planning and competitive differentiation.
"I am very happy with the Polygon Health Analytics team's performance.
They listen to clients' needs and deliver promptly and with high quality.
I will definitely work with them more in the future."